Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | AKT2 | P31751 | 1/20 | 0.57 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.57 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA5A | P35218 | 2/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108709 | 0.91 | AKT1 (0.68) | AKT1KMT2AMEN1TSHRPDPK1 | |
| Orthocresol SCHEMBL16180373 | 0.86 | AKT1 (0.56) | AKT1KMT2AMEN1TSHRPDPK1 | |
| SCHEMBL16180478 | 0.86 | AKT1 (0.56) | AKT1KMT2AMEN1TSHRPDPK1 | |
| SCHEMBL9208171 | 0.83 | AKT1 (0.72) | AKT1KMT2AMEN1TSHRPDPK1 | |
| SCHEMBL282714 | 0.83 | AKT1 (1.00) | AKT1KMT2AMEN1TSHRPDPK1 | |
| SCHEMBL328550 | 0.83 | AKT1 (0.72) | AKT1KMT2AMEN1TSHRPDPK1 | |
| SCHEMBL11891730 | 0.83 | AKT1 (0.80) | AKT1KMT2AMEN1TSHRPDPK1 | |
| SCHEMBL9301440 | 0.82 | AKT1 (0.69) | AKT1KMT2AMEN1TSHRPDPK1 | |
| SCHEMBL11891722 | 0.82 | AKT1 (0.57) | AKT1KMT2AMEN1TSHRPDPK1 | |
| SCHEMBL3154274 | 0.81 | CA1 (0.61) | AKT1KMT2AMEN1TSHRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| US-11432547-B2 | Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220016146-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | Smilebiotek Zhuhai Limited (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20220015338-A1 | ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS | Smilebiotek Zhuhai Limited (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20200396995-A1 | INHIBITORS OF GRB2-ASSOCIATED BINDING PROTEIN 1 (GAB1) AND METHODS OF TREATING CANCER USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-24 | — | — | US | disclosed |
| WO-2020113759-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020113373-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020098630-A1 | ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS | ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) | 2020-05-22 | — | — | WO | disclosed |
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| CN-101282951-A | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI AVENTIS (FR) | 2008-10-08 | — | — | CN | disclosed |
| EP-1937659-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| EP-1937657-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| EP-1937657-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039173-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PPARG, PPARA, PPARD | AKT1 3010/4885KMT2A 2822/4885MEN1 4776/4885 |
| US-20200396995-A1 | INHIBITORS OF GRB2-ASSOCIATED BINDING PROTEIN 1 (GAB1) AND METHODS OF TREATING CANCER USING THE SAME | GAB1, GRB2, BCR | AKT1 878/4885KMT2A 1958/4885MEN1 2912/4885 |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | PPARD, PPARG, PPARA | AKT1 3218/4885KMT2A 3139/4885MEN1 4653/4885 |
| US-11432547-B2 | Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same | GAB1, GRB2, BCR | AKT1 878/4885KMT2A 1958/4885MEN1 2912/4885 |
| US-20220016146-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | AGER, CASP3, PDE6D | AKT1 2726/4885KMT2A 4795/4885MEN1 2125/4885 |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | MB, MYOC, PDE6A | AKT1 3482/4885KMT2A 4843/4885MEN1 1097/4885 |
| US-20220015338-A1 | ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS | MB, MYOC, PDE6A | AKT1 3482/4885KMT2A 4843/4885MEN1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.